<table><tr><td>securities premium</td><td></td><td></td><td></td><td></td></tr><tr><td>Increase in Short Term Borrowings</td><td></td><td>2,072.10</td><td>247.55</td><td>2,431.45</td></tr><tr><td>Increase in Long Term Borrowings</td><td></td><td>4,731.88</td><td>2,078.61</td><td>588.47</td></tr><tr><td>Finance Cost including borrowing cost capitalize</td><td></td><td>(1,470.00)</td><td>(627.52)</td><td>(379.60)</td></tr><tr><td><strong>Net cash flow from financing activities</strong></td><td><strong>C</strong></td><td><strong>5,333.98</strong></td><td><strong>1,698.62</strong></td><td><strong>2,640.34</strong></td></tr><tr><td><strong>Net Increase/(Decrease) In Cash & Cash Equivalents</strong></td><td><strong>(A+B+C)</strong></td><td><strong>(707.47)</strong></td><td><strong>(5,188.09)</strong></td><td><strong>2,505.82</strong></td></tr><tr><td><strong>Cash and Cash equivalents at the beginning of the year</strong></td><td></td><td><strong>1,971.43</strong></td><td><strong>7,159.53</strong></td><td><strong>4,653.71</strong></td></tr><tr><td><strong>Cash and Cash equivalents at the end of the year</strong></td><td></td><td><strong>1,263.95</strong></td><td><strong>1,971.43</strong></td><td><strong>7,159.53</strong></td></tr></table>

<table><thead><tr><th>Notes :-</th><th></th><th>31-03-2025</th><th>31-03-2024</th><th>31-03-2023</th></tr></thead><tbody><tr><td>1.</td><td>Component of Cash and Cash equivalents</td><td></td><td></td><td></td></tr><tr><td></td><td>Cash on hand</td><td>43.03</td><td>88.34</td><td>99.28</td></tr><tr><td></td><td>Balance With banks</td><td>36.59</td><td>25.84</td><td>6,237.41</td></tr><tr><td></td><td>Other Bank Balance (As per AS -3)</td><td>1,184.33</td><td>1,857.24</td><td>822.83</td></tr><tr><td></td><td><strong>Total</strong></td><td><strong>1,263.95</strong></td><td><strong>1,971.43</strong></td><td><strong>7,159.53</strong></td></tr></tbody></table>

2. Cash flows are reported using the indirect method, whereby profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from regular revenue generating, financing and investing activities of the company are segregated.

The accompanying summary of significant accounting policies, restated notes to accounts and notes on adjustments for restated standalone financial Statement (Annexure IV & V, Annexure X to AC) are an integral part of this statement.

As per our consolidated report of even date
For R K Jagetiya & Co
Chartered Accountants
FRN 146264W

FOR AND ON BEHALF OF THE BOARD
Q- Line Biotech Limited

Saurabh Garg
Managing Director & CHAIRMAN
DIN: 02891621

Amita Garg
Whole-Time Director
DIN: 02891610

(CA Ravi K Jagetiya)
M. No. 134691
Proprietor
Date: 24th September, 2025
Place: Mumbai
UDIN-: 25134691BMGTLA9821

Akhand Pratap Singh
Company Secretary
PAN: CFRPS7649R
Date: 24th September, 2025
Place: Lucknow

Meenal Gupta
Chief Financial Officer
PAN -:ABHPG6642E